|Articles|June 1, 2002
Latanoprost plus brimonidine controls IOP
Austin, TX-Patients who need more than one ocular hypotensive agent to achieve low IOP may benefit more from a regimen of latanoprost (Xalatan, Pharmacia) and adjunctive brimonidine (Alphagan, Allergan) than from dual therapy with latanoprost and timolol, according to a recent study.
Advertisement
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
Kodiak Sciences releases follow-up, 20-week data from APEX study
2
Opus Genetics has Type B RMAT meeting with FDA for its gene therapy candidate, OPGx-LCA5
3
From then to next: Five decades of transformation in ophthalmology
4
PolyActiva and RareSight partner to develop treatments for rare pediatric retinal diseases
5














































.png)


